The Economic Outlook Clouds Over, Weighing on the Market, but Two Pharmaceutical Giants May Buck the Trend Jun 8, 2026 Life Science
Gene Editing Could Become the Next “Golden Rush” in the Pharmaceutical Industry, What Does This Mean for CRISPR Therapeutics? Jun 3, 2026 Life Science
AbbVie Faces a Challenger in Johnson & Johnson, but Investors Need Not Panic Jun 3, 2026 Life Science
Riding on Strong Earnings and a $1.5 Billion Market Catalyst, Exelixis Is Poised for Takeoff May 28, 2026 Life Science
With the Macroeconomic Environment Improving, these Three Biotech Stocks Are Worth Watching May 21, 2026 Life Science
Dyne Therapeutics Stock Rises 40% in a Year, but Saturn V Fund Reduces Holdings May 20, 2026 Life Science
